1,019 filings
Page 12 of 51
4
x329lw85
19 Jun 20
Cardiff Oncology / THOMAS PHD ADAMS ownership change
4:15pm
8-K
6zg6vx rynftw4h
19 Jun 20
Departure of Directors or Certain Officers
9:05am
424B5
wasuzjh2cf 18oehj5yf
17 Jun 20
Prospectus supplement for primary offering
11:54am
8-K/A
afq oxvorldjmk0k
17 Jun 20
Other Events
12:00am
8-K
e6vfdoh
16 Jun 20
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
4:26pm
8-K
jnp20
15 Jun 20
Other Events
11:50am
8-K
0j1j73jgv
9 Jun 20
Other Events
11:26am
SC 13G
adz1u5 5b9xzw1v
4 Jun 20
Cardiff Oncology / ACORN BIOVENTURES ownership change
4:14pm
424B3
v97onwnfj923 5zbazr
3 Jun 20
Prospectus supplement
4:01pm
EFFECT
pcdtrjh2vnr5a
3 Jun 20
Notice of effectiveness
12:15am
D
tr3c6u
1 Jun 20
$2.5M in equity / options / securities to be acquired, sold $2.5M, 1 investor
3:46pm
8-K
t6ymw52ig709txh
29 May 20
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
12:00pm
UPLOAD
m2h1ubnrqxx
29 May 20
Letter from SEC
12:00am
CORRESP
nvqdcgbjs0dfq xf3aew
29 May 20
Correspondence with SEC
12:00am
8-K
47bdx2 hzo2k6b79l
28 May 20
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
11:50am
424B5
3mran5qmv 23
27 May 20
Prospectus supplement for primary offering
4:29pm
8-K
89yrvof868v4
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
D
136b2z3
21 May 20
$810K in equity, sold $810K, 8 investors
4:05pm
8-K
5okoy98u
19 May 20
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
9:28am